Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A histological confirmed invasive breast cancer~2. Patient with at least one measurable brain metastatic tumor (≧10mm on T1-weighted gadolinium enhanced MRI or contrast-enhanced CT) or leptomeningeal metastasis with positive CSF cytology study.~3. Patient whose brain parenchymal metastatic tumors either progress after WBRT, develop new lesions after WBRT, or CNS metastatic tumor do not response to WBRT according to image study 3 months after treatment. Patients with leptomeningeal metastasis does not necessarily need whole brain radiotherapy before enrollment.~4. Patients with Her2/neu overexpression or amplification will be allowed but will be informed about other available treatment options such as lapatinib plus capecitabine.~5. Patients must have adequate organ and marrow reserve measured within 14 days prior to randomization as defined below:~   * Absolute neutrophil count ≧1,000/mcL~  * Platelets ≧75,000/mcL~  * Total bilirubin ≦ 1.5 X upper normal limit~  * AST(SGOT)/ALT(SGPT) ≦ 2.5 X upper normal limit; for patients with liver metastases AST(SGOT)/ALT(SGPT) ≦ 5 X is allowed~  * Serum creatinine ≦ upper normal limit or creatinine clearance ≧50ml/min~  * Hemoglobin≧8.0 gm/dL~  * PTT ≦ upper normal limit; INR ≦ 1.5~  * Proteinuria ≤ 1+, if \> 1+, urine protein must be ≦ 1 g/24 hours~6. Patient age 18 to 75 years~7. Patient's life expectancy is more than 2 months~8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1, 2 or 3~9. All women of childbearing potential must have a negative pregnancy test obtained within 72 hours before starting therapy~10. Patients with reproductive potential must use effective contraception (hormone or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 2 months after the completion of therapy~11. Patients (or a surrogate) must be able to comply with study procedures and sign informed consent~Exclusion criteria:~1. Prior therapy with bevacizumab, sorafenib, sunitinib, or other VEGF pathway-targeted therapy~2. Patients whose CNS metastasis progressed or developed during prior cisplatin treatment~3. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding~4. History of thrombotic disorders~5. Active gastrointestinal bleeding~6. Patients with a history of self-reported intra-cranial hemorrhage~7. Patients with clinical signs or symptoms of gastrointestinal obstruction and who require parenteral hydration and/or nutrition because of obstruction~8. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of first dose of bevacizumab~9. Clinically significant peripheral artery disease~10. Arterial thromboembolic event within the past 6 months, including transient ischemic attack, cerebrovascular accident, unstable angina, or myocardial infarction~11. History of gross hemoptysis (i.e. ≥ 1 teaspoon of bright red blood)~12. Other malignancy within 5 years except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~13. Psychiatric illness or social situation that would preclude study compliance~14. Serious non-healing wound, ulcer, or bone fracture~15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment~16. Prior minor surgery or needle biopsies within 7 days~17. Concurrent chronic daily aspirin (\> 325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, non-steroidal anti-inflammatory agents known to inhibit platelet function~18. Concurrent therapeutic anticoagulation, but prophylactic anti-coagulation of venous access devices is allowed~19. History of allergic reaction to compounds of similar chemical composition to the study drugs~20. Pregnancy or lactation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab, etoposide, cisplatin (BEEP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete